Arbutus Biopharma (Formerly Known As Tekmira Pharmaceuticals Corporation)
3805 Old Easton Road
Doylestown, PA 18902
8900 Glenlyon Parkway
Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.
October 6, 2005
CEO: Mark Murray
CMO (Medical): Mark Kowalski
CFO: Bruce Cousins
CSO (Scientific): Michael Sofia
CTO: Peter Lutwyche
Please click here for Arbutus job opportunities.
Please click here for clinical trial information.